OLSALAZINE manufacturers
- Olsalazine
-
- $0.00 / 1kg
-
2026-01-27
- CAS:15722-48-2
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 20tons
- Olsalazine-13C6
-
- $2300.00 / 1mg
-
2025-12-22
- CAS:
- Min. Order:
- Purity:
- Supply Ability: 10g
- OLSALAZINE
-
- $1.00 / 1KG
-
2020-01-05
- CAS:15722-48-2
- Min. Order: 1KG
- Purity: 95-99%
- Supply Ability: 1ton
|
| | OLSALAZINE Basic information |
| Product Name: | OLSALAZINE | | Synonyms: | Ph-CJ-91B;4,4'-Dihydroxyazobenzene-3,3'-dicarboxylic acid;5,5'-Azodisalicylic acid;3,3'-(1,2-diazenediyl)bis[6-hydroxy-Benzoic acid;OLSALAZINE;3,3’-azobis(6-hydroxy-benzoicaci;3,3’-azobis(6-hydroxybenzoicacid);5,5’-azobis(salicylicacid) | | CAS: | 15722-48-2 | | MF: | C14H10N2O6 | | MW: | 302.24 | | EINECS: | 605-089-5 | | Product Categories: | | | Mol File: | 15722-48-2.mol |  |
| | OLSALAZINE Chemical Properties |
| Melting point | >300 °C(Solv: acetic acid (64-19-7); water (7732-18-5)) | | Boiling point | 443.29°C (rough estimate) | | density | 1.3578 (rough estimate) | | refractive index | 1.6500 (estimate) | | solubility | DMSO: soluble
Methanol: soluble | | pka | 2.40±0.10(Predicted) | | form | Solid | | color | Light yellow to yellow | | Water Solubility | 11.49ug/L(25 ºC) | | CAS DataBase Reference | 15722-48-2(CAS DataBase Reference) |
| | OLSALAZINE Usage And Synthesis |
| Uses | Anti-inflammatory (gastrointestinal). | | Indications | Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | | Definition | ChEBI: An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease. | | Brand name | Dipentum (UCB). | | Mechanism of action | Olsalazine is approved for maintenance of remission
of ulcerative colitis, but a commonly reported
side effect is a paradoxical increase in diarrhea. The
U. S. Food and Drug Administration (FDA) has approved
balsalazide disodium (Colazal) as a treatment of
mild to moderately active ulcerative colitis. | | Veterinary Drugs and Treatments | Olsalazine is used for treatment of dogs with chronic colitis that either
cannot tolerate the adverse effects associated with sulfasalazine
or the response to sulfasalazine has been ineffective. | | References | [1] S. NUGENT. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs[J]. Gut, 2001, 48 1: 571-577. DOI: 10.1136/gut.48.4.571
[2] R. PAMUKCU E C S Hanauer. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.[J]. Gastroenterology, 1988, 95 4 1: 975-981. DOI: 10.5555/uri:pii:0016508588901722
[3] A Q MOHSEN. Effects of olsalazine in the jejunum of the rat.[J]. Gut, 1987, 28 3: 346-352. DOI: 10.1136/gut.28.3.346
[4] S MURTHY. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis.[J]. Inflammation Research, 1997, 46 6: 224-233. DOI: 10.1007/s000110050177
[5] YANFEN NIU . Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity[J]. Journal of pharmacological sciences, 2017, 135 3: Pages 114-120. DOI: 10.1016/j.jphs.2017.10.007 |
| | OLSALAZINE Preparation Products And Raw materials |
|